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Abstract Purpose: Infections
caused by antimicrobial-resistant
bacteria (AMRB) are increasing
worldwide, especially in intensive
care units (ICUs). Chlorhexidine
body washing (CHG-BW) has been
proposed as a measure to limit the
spread of AMRB. We have system-
atically assessed the evidence on the
effectiveness of CHG-BW in reduc-
ing colonization and infection with
AMRB in adult ICU patients. Meth-
ods: PubMed, Embase, CINAHL,
and OpenSigle databases were sear-
ched using synonyms for ‘‘intensive
care unit,’’ ‘‘hospital,’’ and ‘‘chlorh-
exidine.’’ All potentially relevant
articles were examined by two inde-
pendent reviewers. Inclusion was
limited to studies with ICU patients as
domain, providing outcomes related
to colonization or infection with
AMRB. Data from 16 studies were
extracted; 9 were excluded because of
assessed high risk of bias or inade-
quate analyses. The remaining studies
differed markedly in (co-)interven-
tions and case mix, which precluded
pooling of data in a formal meta-
analysis. Results: Incidences of
MRSA acquisition were reduced sig-
niﬁcantly in three studies in which
this was the primary endpoint. Sig-
niﬁcant reduction in MRSA infection
rates was observed in only one of ﬁve
studies. Carriage and bacteremia rates
of VRE were assessed in one study,
and both signiﬁcantly declined. There
were hardly any data on the effects of
CHG-BW on antibiotic-resistant
gram-negative bacteria (ARGNB).
Conclusions: CHG-BW may be
effective in preventing carriage, and
possibly bloodstream infections, with
MRSA and VRE in different ICU
settings. As CHG-BW protocols, co-
interventions and case mix varied
widely, attribution of these effects to
CHG-BW alone should be done with
care. Evidence that CHG-BW reduces
carriage of or infections with AR-
GNB is lacking.
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Introduction
The failing control of antimicrobial-resistant bacteria
(AMRB) is an important and continuously growing threat
to the delivery of adequate medical care in hospitals and
the community [1]. Infections caused by AMRB usually
require longer and more complex treatments than those
caused by susceptible bacteria [2, 3]. Nosocomial infec-
tions with AMRB are associated with delayed initiation of
appropriate therapy, failure of therapy, prolonged length
of hospital stay, and increased mortality.
Patients admitted to the intensive care (ICU) are
extremely prone to infections, including those caused by
AMRB. Main contributing factors are underlying
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DOI 10.1007/s00134-012-2542-z REVIEWimmunodeﬁciency, co-morbidities, use of invasive devi-
ces, and the intensity of patient care. These factors,
combined with extensive use of antibiotics, facilitate
patient-to-patient transfer of AMRB [4].
Chlorhexidine gluconate (CHG) is a cationic bis-
biguanide developed in the UK around 1950. Recently,
there has been a renewed interest in this antiseptic as a
measure to prevent infections with, and transmission of,
AMRB in ICU patients. Cross-transmission of AMRB is
extremely important in the dynamics of these bacteria,
and temporarily contaminated hands of health care
workers are considered the most important vectors for
spread [5]. AMRB frequently colonize the skin of ICU
patients, and decontamination of these body surfaces may
not only prevent development of infections but also
reduce the potential for cross-transmission.
We aimed to evaluate the evidence for the effectiveness
of chlorhexidine body washings (CHG-BW) in reducing
colonization and infection with AMRB in adult ICU
patients, measured as colonization or infection with methi-
cillin-resistant Staphylococcus aureus (MRSA),
vancomycin-resistantEnterococci(VRE),and/orantibiotic-
resistantgram-negativebacteria(ARGNB).Weassessedthe
effect, when possible, on different AMRB separately, as the
effectmightdifferbetweenbacterialspecies.Wefocusedon
CHG-BW, and not on the use of CHG for oral decontami-
nation and pre-surgical skin preparation, which have been
systematically reviewed recently [6, 7].
Materials and methods
Search strategy
Methods and inclusion criteria of the review were speci-
ﬁed in advance and documented in a protocol (see
‘‘Appendix’’). All studies in PubMed, Embase, CINAHL,
and OpenSigle from their inception to 1 April 2011 were
considered. Databases were searched using ‘‘intensive
care unit’’ and ‘‘hospital’’ (all variants and abbreviations)
with Boolean ‘‘OR’’ to describe the setting and ‘‘chlorh-
exidine’’ OR ‘‘body wash’’ to describe the intervention. In
OpenSigle, only ‘‘chlorhexidine’’ was used as search term
to include all possibly relevant studies. We included all
studies of adult ICU patients that investigated CHG-BW
as an intervention to control AMRB and had colonization,
clearance of colonization, or infection as an outcome.
Non-English language papers were accepted if they ful-
ﬁlled the above-mentioned criteria. A related article and
reference search was performed.
Data collection and selection of studies
Duplicates were removed, and the title and abstract of all
identiﬁed articles were screened for relevance, without
blinding to journal and authors, by two independent
reviewers (LD and MD). In case of discordant results
consensus was reached by discussion with a third
reviewer (MB). Reviews were included if there was any
reason to assume that original data were present. Letters
to scientiﬁc journals were not automatically excluded, as
they could contain original data. Outbreak reports (an
outbreak was deﬁned as an increase in incidence lasting
\6 months) were excluded, as success in outbreak situ-
ations cannot be generalized to non-outbreak situations.
Chart reviews were also excluded. Studies were eligible if
the setting was the ICU, or hospital without explicit
absence of an ICU, and if outcomes were related to col-
onization or infection with AMRB.
All potentially relevant articles were obtained, and the
full text was examined. Because of the high proportion of
studies with low quality design, a high possibility for bias
or the absence of a control group, we decided at this point
to limit inclusion to randomized controlled trials (RCTs)
and interrupted time series (ITS) design with three or
more time-points. In before–after design studies, proper
ITS analyses and at least three time points before and
after initiation of the intervention are recommended [8,
9]. Even then, there is a possibility that the internal
validity of ITS is compromised by trends that are already
present before the start of intervention, outcomes that are
measured differently over time, and differential dropout
in the intervention group. Therefore, we only selected ITS
adhering to the recommendations of the Cochrane
‘‘Effective Practice and Organization of Care’’ Group
(EPOC) [8] in order to limit these threats to internal
validity.
None of the studies including hospital patients inclu-
ded results for ICU patients separately, nor could these
results be calculated from the data presented. Therefore,
we excluded these studies. The data collection ﬂowchart
is shown in Fig. 1.
Data extraction and management
For each of the 16 included studies, the following char-
acteristics were extracted: design, setting, domain, co-
interventions, outcome(s), possible sources of bias,
missing data, and the statistical analyses used to evaluate
the outcome(s). Only effect measures related to coloni-
zation and/or infection were included.
Only one study (one out of two RCTs) used the ICU
rather than the individual patient as unit of analysis [10].
Because of this sparseness of RCTs using unit-based
analyses, we did not exclude any studies based on this
issue. As many studies did not mention missing data, nor
the way missing data were handled, this was only asses-
sed when present. Because of heterogeneity in designs, no
meta-analyses to obtain pooled results could be
performed.
932Results
Our search yielded 2,477 abstracts; two extra records were
retrieved by related article and reference search [11, 12]. In
both articles, neither ‘‘chlorhexidine’’ nor any of the other
search terms were mentioned in the title or abstract. Seven
studies were included in the ﬁnal review (Table 1)[ 10, 13–
18].Oneofthesestudiesinvestigatedtwointerventionsina
2 9 2factorialdesign.Patients(n = 515)wererandomized
to receive topical antibiotics (polymyxin and tobramycin;
appliedinthe oropharynxandthroughthenasogastric tube)
or placebo, and also to receive mupirocin ointment in the
nose and CHG-BW or placebos. For the current review we
only used the data from the patient groups that did not
receive topical antibiotics, but CHG-BW with mupirocin
(n = 130)orplacebos(n = 126).Ofnineexcludedstudies,
seven were excluded based on inadequate analyses of ITS
studies (following EPOC criteria) [19–25]. In one RCT and
one ITS, insufﬁcient data were present to calculate the
effectiveness of CHG-BW (Table 2)[ 26, 27].
Quality and completeness of the evidence
Of seven included studies three determined acquisition
rates of MRSA carriage [13, 15, 16]; one determined
acquisition rates of VRE carriage [15]. Five quantiﬁed
MRSA [14–18] and one quantiﬁed VRE infection rates
[15]. Four studies reported (limited) results on infections
with ARGNB [10, 14, 16, 17].
Co-interventions were used in four studies [13, 14, 16,
18], and CHG-BW protocols as well as patient case mix
differed extensively between studies (Table 1).
Compliance with CHG-BW protocol was measured in
one study only [15]. In this study, actual use of CHG was
compared to predicted use, and coordinators urged better
compliance if needed. However, compliance data were
not presented. Hand hygiene compliance was not sys-
tematically assessed in any of the studies.
Risk of bias in included studies
There was no perceived risk of selection bias in the
selected studies. In one study, 3,928 of 4,444 admitted
ICU patients were excluded, but only 4.6 % of these
patients were excluded for other reasons than those stated
in the exclusion criteria [mainly because of logistic issues
on weekends (3.7 %)] [14].
A double-blind design was used in one [14] and partial
blinding in another RCT in which one of three investi-
gators categorizing bloodstream infections (BSIs) and the
category adjudicator were blinded to the study arm [10].
Naturally, blinding was not used in the studies with ITS
design.
Possibilities for detection bias were considered present
in three studies [13, 15, 16]. In one study the method of
screening changed during the trial [13]; in another one
compliance with obtaining surveillance cultures increased
during the study [15], and in the third study screening
cultures were used during intervention, but not during the
baseline period [16]. In the latter two studies, though,
detection bias may have underestimated the effectiveness
of the intervention, as detection of the primary endpoint
improved after the intervention was implemented.
Attrition bias was not considered relevant in any of the
included studies. In one study 3 of 391 patients in the
CHG-BW arm did not receive bathing because of skin
rashes (eventually considered as not related to CHG-BW),
and these patients were included in the intention-to-treat
analysis [10]. In another study 1 of 126 patients in the
placebo group was withdrawn from the analysis because
of premature unblinding [14].
Though no formal meta-analysis was performed, the
presence of studies with negative results demonstrates
that publication bias was not complete.
Selective outcome reporting may have been present,
but was difﬁcult to assess as study protocols for studies
Fig. 1 Study ﬂow diagram
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934using an ITS design were not available. Protocols were
available for the two RCTs. For one RCT the protocol, as
accessed through http://www.clinicaltrials.gov, stated that
microbiological data were collected, but only data related
to BSIs were reported [10]. The authors stated that these
data will be published separately. The protocol of the
other RCT was kindly provided by the authors, and no
risk of selective outcome reporting was detected [14]. For
the ITS studies, we compared information in the ‘‘meth-
ods’’ sections to the ‘‘results’’ sections, and evidence of
selective outcome reporting was not detected. In one of
these studies, it was stated that the intervention was not
part of a pre-planned study protocol [17].
Effects of interventions
Incidences of acquisition of MRSA carriage were reduced
signiﬁcantly in the three studies in which this was the
primary endpoint (Table 3)[ 13, 15, 16].
MRSA infection rates were a primary outcome in
three studies [15, 16, 18], and two studies presented
limited data on MRSA infection rates [14, 17]. A statis-
tically signiﬁcant incidence reduction was observed in
one [18]. Two studies failed to demonstrate statistically
signiﬁcant effects on MRSA bacteremia, although
MRSA-carriage rates decreased in both studies [15, 16].
Absolute numbers of MRSA bacteremia, though, were
only 40 (29 before and 11 after intervention) and 13 (8
before and 5 after intervention) in these studies. MRSA
infections were even lower in the studies in which this
was not a primary outcome. In one study there were two
and ﬁve MRSA infections in the CHG-BW and placebo
group [14], and in the other study there were ﬁve and six
clinical cultures yielding MRSA at baseline and during
the intervention, respectively (incidence rate of 0.68 vs.
1.03 per 1,000 patient-days; p = 0.49) [17].
Carriage and bacteremia rates due to VRE were ana-
lyzed in one study; these were reduced by 45 and 78 %,
respectively [15].
Reported results of CHG-BW on preventing all-cause
infections were more heterogeneous. There was a statis-
tically signiﬁcant 61 % decline in the incidence of all-
cause primary BSIs in one study [10], whereas no sig-
niﬁcant reductions in central line-associated BSIs
(CLABSIs) were reported in two other studies [14, 17].
Although incidences of colonization and/or infections
with ARGNB were not primary outcomes in any of the
studies, some results were provided. In one study, 1 out of
27 and 2 out of 11 primary BSIs were caused by gram-
negative bacteria before and after the introduction of
CHG-BW, respectively [10]. In another study, 5 out of 13
and 1 out of 12 clinical cultures grew imipenem-resistant
A. baumannii before and during the use of CHG-BW,
respectively, although overall more CLABSIs were due to
gram-negative bacteria (and yeasts) during CHG-BW
[17]. In a third study, the number of patients acquiring
infections with gram-negative bacteria was 50 of 126
randomized to placebo and 44 of 130 randomized to
CHG-BW plus nasal mupirocin, without further infor-
mation on antibiotic susceptibilities [14]. In a fourth
study, carriage and bacteremia rates with ARGNB were
1 % or lower in both study periods [16]. Therefore, there
was hardly any evidence on the effects of CHG-BW on
carriage with ARGNB.
Discussion
The results of this systematic review demonstrate that
CHG-BW may be effective in preventing bloodstream
infections and carriage with MRSA and VRE in different
ICU settings. This conclusion is based on seven studies
with good methodological quality and low risk of bias,
but marked differences in interventions, co-interventions
and patient case mix, which precluded pooling of data in a
formal meta-analysis.
Though much can be learned from less robust studies,
like outbreaks, we chose methodological selection criteria
Table 2 Characteristics of excluded studies
Study Design Reason for exclusion
Dixon [19] ITS Does not use time-series analysis. Source and method of data collection not mentioned
Dryden [26] RCT CHG-BW was used in both groups
Evans [20] ITS Does not use time-series analysis
Fraser [21] ITS Does not use time-series analysis
ITS with only one data point per period
Holder [22] ITS No formal analysis, only descriptive data. High risk of bias (regression to the mean)
Munoz-Price [23] ITS Does not use time-series analysis. Possible regression to the mean. Risk of reporting bias (the ‘‘unblinded’’
preventionist reported the number of infections). Substantial non-compliance, not quantiﬁed in intervention
period
Popovich [24] ITS Does not use time-series analysis
Ridenour [25] ITS Does not use time-series analysis
Robicsek [27] ITS Not suitable to assess effectiveness of CHG-BW (focus on different types of surveillance)
CHG-BW chlorhexidine gluconate body washing, ITS interrupted time series, RCT randomized controlled trial
935to select only the best available evidence. Before-after
studies not fulﬁlling these criteria have a high chance of
inappropriately attributing the found effect to the inter-
vention, as they do not correct for baseline trends [8].
In four studies, co-interventions were present, such as
the use of mupirocin intranasally, active surveillance
cultures, isolation or other barrier precautions, and edu-
cation programs [13, 14, 16, 18]. Therefore, attribution of
the beneﬁcial effects on infections and carriage with
MRSA and VRE to CHG-BW alone should be made with
care.
There was no evidence (nor lack of evidence) that
CHG-BW reduces acquisition of carriage or infections
with ARGNB. CHG works by attachment to and
disruption of cytoplasmic membranes of bacteria, and
should, therefore, be effective against gram-positive and
-negative bacteria [5]. In vitro, though, CHG has
slightly better activity against gram-positive bacteria
[5].
Possible adverse events and the emergence of resis-
tance against CHG are important issues that were not
systematically assessed. However, no severe allergic skin
reactions were reported in the included studies. In one
study slightly higher median minimally inhibitory con-
centrations to CHG were observed among blood culture
isolates during CHG-BW, compared to soap-and-water
bathing, but this difference was attributed to isolation of
fewer (very susceptible) gram-positive bacteria during
Table 3 Summary of ﬁndings
Study Patients
included
(n)
Duration
(months)
Infection Colonization
Batra [13] 4,570 51 70 % reduction in acquisition of endemic MRSA strains
(rate ratio 0.3), but increased acquisition (rate ratio
3.85) with an outbreak MRSA strain
Bleasdale [10] 836 12 61 % incidence reduction in all-cause primary BSIs; rate
difference 6.3/1,000 ptdays 16.8 versus 6.4 BSIs per
1,000 central line-days (p = 0.01)
No signiﬁcant reduction in all-cause UTI,
VAP, and secondary BSIs
Camus [14] 256 30 No signiﬁcant reduction in all-cause
ICU-acquired infections (p = 0.919)
a
No signiﬁcant reduction in all-cause total infections
a
No signiﬁcant reduction in all-cause
device-related infections
b
Climo [15] 5,043 12 No reduction in MRSA bacteremia
c 25 % reduction in acquisition of MRSA colonization
(-0.66 per 1,000 ptdays)
c
78 % reduction in ICU acquired VRE bacteremias
(-2.64 per 1,000 ptdays)
c
45 % reduction in acquisition of VRE colonization
(-1.51 per 1,000 ptdays)
c
Gould [16] 2,653 48 No signiﬁcant reduction in MRSA or MSSA bacteremia 11.4 decrease (p = 0.005) in proportion of patients with
MRSA (colonization or infection)
Popovich [17] 3,048 24 No signiﬁcant reduction in ICU-acquired all-cause
CLABSIs (p = 0.57)
Signiﬁcant decrease in incidence rate of MRSA clinical
cultures (0.68 versus 1.03 per 1,000 ptdays, p = 0.49)
No signiﬁcant reduction in ICU-acquired
other infections (all p values[0.18)
Raineri [18] 3,978 120 Decrease of MRSA infection rate from 3.5 to 1.7 per
1,000 ptdays (p = 0.0023)
No signiﬁcant difference in MRSA-VAP
Decrease in MRSA-BSI incidence rate from 1.65 to 0.29
cases per 1,000 ptdays (p = 0.02)
BSI bloodstream infection, CHG chlorhexidine gluconate, CHG-BW
chlorhexidine gluconate body washing, CLABSI central line-associated
bloodstream infection, MRSA methicillin-resistant Staphylococcus aureus,
PO primary outcome, Ptdays patient-days, SO secondary outcome, TW-
MRSA sequence type 239 MRSA outbreak strain, UTI urinary tract infec-
tion, VAP ventilator-associated pneumonia, Vent days ventilator days, VRE
vancomycin-resistant Enterococci
a There was a signiﬁcant effect for the polymyxin/tobramycin plus CHG/
mupirocin group when compared to each regimen alone and neither regimen
b There was also no signiﬁcant difference for the polymyxin/tobramycin
plus CHG/mupirocin group when compared to each regimen alone and
neither regimen
c Only the results of the time-series analysis are presented
d For period 1 compared to period 2. For the whole trial (period 1 to period
3), there was a signiﬁcant decrease (p = 0.006 for trend)
936CHG-BW rather than to an increase in the absolute
number of bacteria with elevated minimally inhibitory
concentrations for CHG [10].
Since decontamination of body surfaces may not only
prevent development of infections but also reduce the
potential for cross-transmission, CHG-BW may inﬂuence
the risk of non-treated patients to acquire bacterial car-
riage (i.e., colonization pressure) [28]. The effects of
CHG-BW are, therefore, best evaluated when applied to
all patients in a unit simultaneously, and individual
patient randomization may not be the most appropriate
study design. There was only one RCT in which the
effectiveness of CHG-BW was evaluated on the unit level
[10].
The most practical approach for unit-based interventions
is a before–after study. Unfortunately, from a methodolog-
ical perspective, this is a weak study design because of
intrinsicrisksofbias[9].Moreover,notincorporatingpatient
dependency in the statistical analysis may lead to wrong
inferences [29]. Therefore, seven studies employing ITS
design, but not complying with EPOC guidelines were
excluded from our analyses [19–27].
In a recent meta-analysis of 12 studies investigating
the effects of CHG-BW on the incidence of BSIs, no
methodological criteria were applied for study selection
[30]. Five of those studies were also included in our
study, [10, 14–17], and reductions in BSIs were apparent
in three [10, 15, 16]. However, our study adds important
nuances to the conclusions of O’Horo et al. In one of the
abovementioned three studies, only a reduction in pri-
mary, but not in secondary all-cause BSIs was apparent
[10]; in one study a signiﬁcant reduction in ICU-
acquired VRE bacteremia, but not of MRSA bacteremia
was demonstrated [15], and in the remaining study there
were no reductions in MRSA and MSSA bacteremia in
the original manuscript [16]. The reduction as demon-
strated in the pooled estimate of O’Horo’s meta-analysis
was caused by a decrease in BSI caused by coagulase-
negative staphylococci only [30]. Two studies included
in our review were excluded in O’Horo’s meta-analysis,
one study because the outcome was colonization instead
of infection [13]. The reason for exclusion of the second
study investigating BSIs, albeit with MRSA only, is
unknown [18]. Five studies, excluded for methodological
reasons in our study were included in O’Horo’s study. In
4 of these (from a total of 12 studies) statistically sig-
niﬁcant effects were obtained. Though the authors touch
upon the subject of heterogeneity in their discussion,
they do not comment on their reasons for pooling data.
In summary, both the present study and O’Horo’s meta-
analysis suggest an effect of CHG-BW on BSIs. Our
study adds that the beneﬁt for preventing BSI is limited
to gram-positives (VRE and possibly MRSA) and that
evidence for gram-negatives is lacking. Moreover, our
ﬁndings also suggest that colonization with gram-posi-
tives is reduced by CHG-BW.
Conclusions
Based on this systematic review we conclude that there is
evidence that CHG-BW is effective in preventing car-
riage, and possibly BSI, with MRSA and VRE in ICU
patients, although this evidence is weakened by inter-
study differences in intervention, co-interventions, and
patient case mix. Overall, the quality of the studies was
good, with low to medium risk of bias. There was no
evidence (or lack of evidence) that CHG-BW reduces
acquisition of carriage or infections with ARGNB. Future
studies should address the effects of CHG-BW on
acquisition of carriage and infections with ARGNB,
preferably by investigating the effects of CHG-BW with
the ICU as level of inference to account for colonization
pressure, for instance by applying an ITS design with
sufﬁcient data points or a cluster-randomized trial design.
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Appendix: Research protocol
Objective: To evaluate the evidence for the effectiveness
of the use of chlorhexidine body washings in reducing col-
onization and infection with AMRB in adult ICU patients.
Databasestobesearched:PubMed,Embase,CINAHL,
and OpenSigle from their inception until 1 April 2011. The
search was last performed on 15 September 2011.
Population: Adult ICU patients.
Intervention: Chlorhexidine body washings.
Outcomes: All outcomes related to colonization,
infection, and/or bacteremia with AMRB.
Study design: All.
Free text search terms: chlorhexidine, chlorhexidine
gluconate, critical care, icu, intensive care, critical* ill,
critical* illness, intensive treatment unit*, hospital, hos-
pitals, inpatient*, hospitalis*, hospitaliz*.
MeSH terms: Chlorhexidine (‘‘Chlorhexidine’’[Mesh]),
Chlorhexidine gluconate (‘‘Chlorhexidine gluconate’’[Sub-
stance Name]).
Study selection (after removing duplicates): Screen title
and abstract of all identiﬁed articles for relevance, without
blinding to journal and authors, by two independent
reviewers (LD and MD). In case of discordant results con-
sensus by discussion with a third reviewer (MB).
(A) Inclusion
Body washing with CHG as an intervention to control
AMRB.
937Colonization or infection with MRSA or VRE or AR-
GNB or any combination of those microorganisms or
clearance of colonization with these micro-organisms as an
outcome.
Setting: ICU or hospital without explicit absence of an
ICU.
Patient population: Adults.
Non-English language papers and non-published
papers all accepted.
Reviews included.
Letters to scientiﬁc journals included.
(B) Exclusion
Outbreak reports (deﬁned as an increase in incidence
that lasted\6 months) excluded as having weak evidence.
Chart reviews excluded.
Studies speciﬁcally on the subject of oral or topical
decontamination, and studies on hand hygiene only
excluded.
PubMed search strategy: [(critical care unit* OR ccu
NOT coronary care unit*) OR critical care OR cc OR
intensive care unit* OR icu OR intensive care OR ic
OR (critical* AND ill) OR (critical* AND illness) OR
intensive treatment* OR (intensive treatment* AND
unit)* OR itu OR hospital OR hospitals OR inpatient* OR
hospitaliz* OR hospitalis*] AND (chlorhexidine gluco-
nate* OR chlorhexidine* OR body wash*).
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